# A Study for Patients With Type 2 Diabetes

Study · id `cardio:ct-nct01027871` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01027871](<https://clinicaltrials.gov/study/NCT01027871>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01027871

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 289 participants.

## Technical summary

Registry record NCT01027871. Randomized; no masking; primary purpose treatment. Start 2010-01 (registry gives no type); primary completion 2010-12 (actual). Results posted on 2018-06-08.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 289 participants (enrolled count; ClinicalTrials.gov record NCT01027871, source copy `cardio:ctgov-nct01027871-2018-06-08`, retrieved 2026-10-26)
- Start date: 2010-01 (registry gives no type) (ClinicalTrials.gov record NCT01027871, source copy `cardio:ctgov-nct01027871-2018-06-08`, retrieved 2026-10-26)
- Primary completion: 2010-12 (actual) (ClinicalTrials.gov record NCT01027871, source copy `cardio:ctgov-nct01027871-2018-06-08`, retrieved 2026-10-26)
- Completion: 2011-01 (actual) (ClinicalTrials.gov record NCT01027871, source copy `cardio:ctgov-nct01027871-2018-06-08`, retrieved 2026-10-26)
- Results first posted: 2018-06-08 (ClinicalTrials.gov record NCT01027871, source copy `cardio:ctgov-nct01027871-2018-06-08`, retrieved 2026-10-26)
- Countries: United States; Australia; Hungary; Poland; Puerto Rico; Romania; Russia; Spain (ClinicalTrials.gov record NCT01027871, source copy `cardio:ctgov-nct01027871-2018-06-08`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01027871-2018-06-08`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study for Patients With Type 2 Diabetes
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): LY2605541
- Intervention (Drug): insulin glargine
- Lead sponsor: Eli Lilly and Company
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Eli Lilly and Company (`cardio:eli-lilly`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes (`cardio:pubmed-22787177`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Lower glucose variability and hypoglycemia measured by continuous glucose monitoring with novel long-acting insulin LY2605541 versus insulin glargine (`cardio:pubmed-24198302`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: c6945902b8527cfb168652d5a6b9b60f791fd081b81c775945aff5073f0dd994
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
